Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis

Tina L. Pinto Slottow, Laurent Bonello, Rekha Gavini, Patricia Beauzile, Steven J. Sushinsky, Mickey Scheinowitz, Kimberly Kaneshige, Zhenyi Xue, Rebecca Torguson, Udaya Tantry, Augusto D. Pichard, Lowell F. Satler, William O. Suddath, Kenneth Kent, Paul Gurbel, Ron Waksman

Research output: Contribution to journalArticle

Abstract

Drug-eluting stent (DES) thrombosis has a multifactorial etiology. Variable responsiveness to antiplatelet therapy likely contributes to its pathogenesis. We aimed to determine whether patients who had experienced DES thrombosis compared with a cohort of patients who had not would exhibit greater platelet reactivity and a greater prevalence of aspirin and clopidogrel resistance. The effect of aspirin and clopidogrel on platelet reactivity was determined after angiographically proven DES thrombosis in 26 patients and in 21 patients who had not experienced stent thrombosis (ST) ≥18 months after DES implantation. Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P). Aspirin resistance was present in 23% of patients with ST and 5% of controls (p = NS). Clopidogrel resistance was present in 40% of patients with ST and 14% of controls using the P2Y12 assay (p = 0.02) and 90% of patients with ST and 67% of controls using the VASP-P assay (p = NS). Mean aspirin reaction units were significantly greater among all patients with ST and those with early ST compared with controls (477 ± 89 vs 429 ± 58, p = 0.04; and 485 ± 84 vs 429 ± 58, p = 0.02, respectively). Mean P2Y12 reaction units were significantly greater among patients with early ST compared with controls (265 ± 102 vs 184 ± 76, p = 0.01). The results of the VASP-P assay did not correlate with the presence of ST. In conclusion, patients who experienced DES thrombosis demonstrated significantly greater rates of clopidogrel resistance as determined by P2Y12 reaction units, but not VASP-P, compared with patients without DES thrombosis. Aspirin reaction units were significantly greater in the DES thrombosis population. Point-of-care testing with the VerifyNow Aspirin and P2Y12 Assays has the potential to identify patients at increased risk of ST, particularly early ST, after DES deployment.

Original languageEnglish (US)
Pages (from-to)525-530
Number of pages6
JournalThe American Journal of Cardiology
Volume104
Issue number4
DOIs
StatePublished - Aug 15 2009

Fingerprint

clopidogrel
Drug-Eluting Stents
Aspirin
Thrombosis
Stents
Phosphorylation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pinto Slottow, T. L., Bonello, L., Gavini, R., Beauzile, P., Sushinsky, S. J., Scheinowitz, M., ... Waksman, R. (2009). Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. The American Journal of Cardiology, 104(4), 525-530. https://doi.org/10.1016/j.amjcard.2009.04.015

Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. / Pinto Slottow, Tina L.; Bonello, Laurent; Gavini, Rekha; Beauzile, Patricia; Sushinsky, Steven J.; Scheinowitz, Mickey; Kaneshige, Kimberly; Xue, Zhenyi; Torguson, Rebecca; Tantry, Udaya; Pichard, Augusto D.; Satler, Lowell F.; Suddath, William O.; Kent, Kenneth; Gurbel, Paul; Waksman, Ron.

In: The American Journal of Cardiology, Vol. 104, No. 4, 15.08.2009, p. 525-530.

Research output: Contribution to journalArticle

Pinto Slottow, TL, Bonello, L, Gavini, R, Beauzile, P, Sushinsky, SJ, Scheinowitz, M, Kaneshige, K, Xue, Z, Torguson, R, Tantry, U, Pichard, AD, Satler, LF, Suddath, WO, Kent, K, Gurbel, P & Waksman, R 2009, 'Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis', The American Journal of Cardiology, vol. 104, no. 4, pp. 525-530. https://doi.org/10.1016/j.amjcard.2009.04.015
Pinto Slottow, Tina L. ; Bonello, Laurent ; Gavini, Rekha ; Beauzile, Patricia ; Sushinsky, Steven J. ; Scheinowitz, Mickey ; Kaneshige, Kimberly ; Xue, Zhenyi ; Torguson, Rebecca ; Tantry, Udaya ; Pichard, Augusto D. ; Satler, Lowell F. ; Suddath, William O. ; Kent, Kenneth ; Gurbel, Paul ; Waksman, Ron. / Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. In: The American Journal of Cardiology. 2009 ; Vol. 104, No. 4. pp. 525-530.
@article{259dbb4ba4144d27916cb8817ad07e6b,
title = "Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis",
abstract = "Drug-eluting stent (DES) thrombosis has a multifactorial etiology. Variable responsiveness to antiplatelet therapy likely contributes to its pathogenesis. We aimed to determine whether patients who had experienced DES thrombosis compared with a cohort of patients who had not would exhibit greater platelet reactivity and a greater prevalence of aspirin and clopidogrel resistance. The effect of aspirin and clopidogrel on platelet reactivity was determined after angiographically proven DES thrombosis in 26 patients and in 21 patients who had not experienced stent thrombosis (ST) ≥18 months after DES implantation. Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P). Aspirin resistance was present in 23{\%} of patients with ST and 5{\%} of controls (p = NS). Clopidogrel resistance was present in 40{\%} of patients with ST and 14{\%} of controls using the P2Y12 assay (p = 0.02) and 90{\%} of patients with ST and 67{\%} of controls using the VASP-P assay (p = NS). Mean aspirin reaction units were significantly greater among all patients with ST and those with early ST compared with controls (477 ± 89 vs 429 ± 58, p = 0.04; and 485 ± 84 vs 429 ± 58, p = 0.02, respectively). Mean P2Y12 reaction units were significantly greater among patients with early ST compared with controls (265 ± 102 vs 184 ± 76, p = 0.01). The results of the VASP-P assay did not correlate with the presence of ST. In conclusion, patients who experienced DES thrombosis demonstrated significantly greater rates of clopidogrel resistance as determined by P2Y12 reaction units, but not VASP-P, compared with patients without DES thrombosis. Aspirin reaction units were significantly greater in the DES thrombosis population. Point-of-care testing with the VerifyNow Aspirin and P2Y12 Assays has the potential to identify patients at increased risk of ST, particularly early ST, after DES deployment.",
author = "{Pinto Slottow}, {Tina L.} and Laurent Bonello and Rekha Gavini and Patricia Beauzile and Sushinsky, {Steven J.} and Mickey Scheinowitz and Kimberly Kaneshige and Zhenyi Xue and Rebecca Torguson and Udaya Tantry and Pichard, {Augusto D.} and Satler, {Lowell F.} and Suddath, {William O.} and Kenneth Kent and Paul Gurbel and Ron Waksman",
year = "2009",
month = "8",
day = "15",
doi = "10.1016/j.amjcard.2009.04.015",
language = "English (US)",
volume = "104",
pages = "525--530",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis

AU - Pinto Slottow, Tina L.

AU - Bonello, Laurent

AU - Gavini, Rekha

AU - Beauzile, Patricia

AU - Sushinsky, Steven J.

AU - Scheinowitz, Mickey

AU - Kaneshige, Kimberly

AU - Xue, Zhenyi

AU - Torguson, Rebecca

AU - Tantry, Udaya

AU - Pichard, Augusto D.

AU - Satler, Lowell F.

AU - Suddath, William O.

AU - Kent, Kenneth

AU - Gurbel, Paul

AU - Waksman, Ron

PY - 2009/8/15

Y1 - 2009/8/15

N2 - Drug-eluting stent (DES) thrombosis has a multifactorial etiology. Variable responsiveness to antiplatelet therapy likely contributes to its pathogenesis. We aimed to determine whether patients who had experienced DES thrombosis compared with a cohort of patients who had not would exhibit greater platelet reactivity and a greater prevalence of aspirin and clopidogrel resistance. The effect of aspirin and clopidogrel on platelet reactivity was determined after angiographically proven DES thrombosis in 26 patients and in 21 patients who had not experienced stent thrombosis (ST) ≥18 months after DES implantation. Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P). Aspirin resistance was present in 23% of patients with ST and 5% of controls (p = NS). Clopidogrel resistance was present in 40% of patients with ST and 14% of controls using the P2Y12 assay (p = 0.02) and 90% of patients with ST and 67% of controls using the VASP-P assay (p = NS). Mean aspirin reaction units were significantly greater among all patients with ST and those with early ST compared with controls (477 ± 89 vs 429 ± 58, p = 0.04; and 485 ± 84 vs 429 ± 58, p = 0.02, respectively). Mean P2Y12 reaction units were significantly greater among patients with early ST compared with controls (265 ± 102 vs 184 ± 76, p = 0.01). The results of the VASP-P assay did not correlate with the presence of ST. In conclusion, patients who experienced DES thrombosis demonstrated significantly greater rates of clopidogrel resistance as determined by P2Y12 reaction units, but not VASP-P, compared with patients without DES thrombosis. Aspirin reaction units were significantly greater in the DES thrombosis population. Point-of-care testing with the VerifyNow Aspirin and P2Y12 Assays has the potential to identify patients at increased risk of ST, particularly early ST, after DES deployment.

AB - Drug-eluting stent (DES) thrombosis has a multifactorial etiology. Variable responsiveness to antiplatelet therapy likely contributes to its pathogenesis. We aimed to determine whether patients who had experienced DES thrombosis compared with a cohort of patients who had not would exhibit greater platelet reactivity and a greater prevalence of aspirin and clopidogrel resistance. The effect of aspirin and clopidogrel on platelet reactivity was determined after angiographically proven DES thrombosis in 26 patients and in 21 patients who had not experienced stent thrombosis (ST) ≥18 months after DES implantation. Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P). Aspirin resistance was present in 23% of patients with ST and 5% of controls (p = NS). Clopidogrel resistance was present in 40% of patients with ST and 14% of controls using the P2Y12 assay (p = 0.02) and 90% of patients with ST and 67% of controls using the VASP-P assay (p = NS). Mean aspirin reaction units were significantly greater among all patients with ST and those with early ST compared with controls (477 ± 89 vs 429 ± 58, p = 0.04; and 485 ± 84 vs 429 ± 58, p = 0.02, respectively). Mean P2Y12 reaction units were significantly greater among patients with early ST compared with controls (265 ± 102 vs 184 ± 76, p = 0.01). The results of the VASP-P assay did not correlate with the presence of ST. In conclusion, patients who experienced DES thrombosis demonstrated significantly greater rates of clopidogrel resistance as determined by P2Y12 reaction units, but not VASP-P, compared with patients without DES thrombosis. Aspirin reaction units were significantly greater in the DES thrombosis population. Point-of-care testing with the VerifyNow Aspirin and P2Y12 Assays has the potential to identify patients at increased risk of ST, particularly early ST, after DES deployment.

UR - http://www.scopus.com/inward/record.url?scp=67849117309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67849117309&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.04.015

DO - 10.1016/j.amjcard.2009.04.015

M3 - Article

VL - 104

SP - 525

EP - 530

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -